Investigating how a specific protein affects blood vessel growth in the eye
Official title: Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis
Funded at Boston Children's Hospital · NIH-10898710 · Data updated 2026-11-12
This study is looking at a protein called CMG2 to see how it affects the growth of blood vessels in the eye, with the hope of finding new ways to stop unwanted blood vessel growth that can lead to vision loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $410,004 |
| NIH project number | 5R01EY033354-03 |
| Project ID | NIH-10898710 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals at risk for corneal graft rejection or those suffering from conditions related to abnormal blood vessel growth in the eye.
✕Less likely to help
Patients with conditions unrelated to angiogenesis or those not experiencing vision-related issues may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called CMG2 in the process of blood vessel formation, particularly in the eye. By using advanced techniques to observe how endothelial cells move towards growth factors, the researchers aim to uncover how targeting CMG2 can inhibit unwanted blood vessel growth, which is a major cause of vision loss. The study employs a microfluidic migration assay to track individual cell movements, allowing for a detailed analysis of both random movement and directed movement towards signals. The findings could lead to new treatments for conditions like corneal neovascularization and other diseases associated with abnormal blood vessel growth.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent vision loss by targeting abnormal blood vessel growth in the eye.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways for treating angiogenesis-related conditions, indicating potential for success in this approach.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Rogers, Michael Sean — Boston Children's Hospital
- Study coordinator: Rogers, Michael Sean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.